ASCO 2026: Highlights and analysis

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Bupropion shows benefit for cancer-related fatigue in cancer survivors

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Short-term fasting linked to improved chemo response in advanced ovarian cancer

FMISO PET-guided radiation dose de-escalation maintains long-term outcomes in HPV-associated oropharyngeal cancer

ASCO 2026: Latest in prostate cancer

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

GLP-1 therapy associated with reduced breast cancer risk

Structured exercise programme improves survival and reduces healthcare costs in colon cancer